Abstracts Archive - Page 197 of 2607 - ACR Meeting Abstracts

Abstract Number: 2656 • ACR Convergence 2024
Short-Term Effectiveness of a Walk with Ease Program Delivered by Telephone on Arthritis-Related Symptoms, Function, and Physical Activity
Christine Pellegrini, Sara Wilcox, Yesil Kim, Katherine Devivo, Scott Jamieson, Kailyn Horn and Daniel Heidtke, University of South Carolina, Columbia, SC
Background/Purpose: Walk With Ease (WWE) is a 6-week arthritis-appropriate evidence-based physical activity program traditionally offered in a face-to-face format. However, as many populations encounter participation…
Abstract Number: 2626 • ACR Convergence 2024
Identifying Homogeneous Endophenotypes in Childhood-Onset Systemic Lupus Erythematosus with Similarity Network Fusion
Nicholas C Chan¹, Nicholas Gold², Deborah Levy², Andrea Knight³, Earl Silverman⁴, Daniela Dominguez⁵, Lawrence Ng², Lauren Erdman² and Linda Hiraki², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴Silverman, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, Canada
Background/Purpose: Childhood-onset Systemic Lupus Erythematosus (cSLE) is a clinically heterogeneous autoimmune disease. We hypothesized that similarity network fusion (SNF) a data driven method would identify…
Abstract Number: 2633 • ACR Convergence 2024
Multicenter Validation of a Machine Learning Foundation Model to Diagnose Sjögren’s Disease and Identify Histological Biomarkers for Disease Stratification
Julien Duquesne¹, Charlotte Claye¹, Louis Basseto¹, Michael Barnes², Elena Pontarini³, Amaya Syed², Michele Bombardieri⁴, Benjamin A. Fisher⁵, SABA NAYAR⁵, Andreas Goules⁶, Athanasios Tzioufas⁷, Loukas chatzis⁸, Wan Fai Ng⁹, Bec Scane¹⁰, Matilde Bandeira¹¹, Vasco C. Romão¹², Thierry Lazure¹³, Clovis Adam¹⁴, Xavier Mariette¹⁵, Samuel Bitoun¹⁶ and Vincent Bouget¹⁷, and NECESSITY Consortium, ¹Scienta Lab, Paris, France, ²William Harvey Research institute, Centre for Translational Bioinformatics, London, United Kingdom, ³William Harvey Research Institute, London, United Kingdom, ⁴Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ⁵University of Birmingham, Birmingham, United Kingdom, ⁶GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, ⁷LAIKO HOSPITAL, Athens, Greece, ⁸Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ⁹Department of Rheumatology, Newcastle University, & HRB Clinical Research Facility, University College Cork, Newcastle upon Tyne, United Kingdom, ¹⁰Department of Rheumatology, Newcastle University, Athens, Greece, ¹¹Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, ¹²Rheumatology Department, ULS Santa Maria & Rheumatology Research Unit, Instituto Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, ¹³APHP. Université Paris-Saclay, Hôpital Bicêtre, Anatomie et cytologie pathologiques, Paris, France, ¹⁴APHP. Université Paris-Saclay, Hôpital Bicêtre, Laboratoire de neuropathologie, Paris, France, ¹⁵Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ¹⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, ¹⁷Scienta Lab, Gif-sur-Yvette, France
Background/Purpose: Sjögren’s Disease (SjD) classification relies on the EULAR/ACR 2016 criteria: i) quantifying lymphocyte infiltration in labial salivary gland (LSG) biopsies, ii) autoantibody status and…
Abstract Number: 2593 • ACR Convergence 2024
A Long-term Synovial Tissue 3D Model Incorporating Fibroblasts, Macrophages, Endothelial Cells, and Other Immune Cells Such as Innate Lymphoid Cells Enables Animal Model-Independent Rheumatoid Arthritis Research
Miriam Bollmann¹, Oskar Landberg², Negar Ayoubzadeh², Charlotte A. Jonsson², Inger Gjertsson² and Mattias Svensson², ¹University of Gothenburg, Göteborg, Sweden, ²University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with multiple tissues contributing to its pathology, including the synovial membrane. The RA synovial membrane…
Abstract Number: 2605 • ACR Convergence 2024
Clarifying Misbeliefs & Resolving Decisional Conflicts About Hydroxychloroquine (HCQ) Through a Shared Decision-Making Tool (HCQ-SAFE©)
Shivani Garg¹, Jay Patel¹, Sancia Ferguson², Betty Chewning³, Shelby Gomez⁴, Jon keevil⁵, David Gazeley⁶, Patricia Tellez-Giron¹ and Christie Bartels⁷, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²University of Wisconsin, Madison, Madison, WI, ³University of Wisconsin, School of Pharmacy, Madison, ⁴UW Health, Madison, ⁵N/A, Madison, ⁶Medical College of Wisconsin, Wauwatosa, WI, ⁷University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Treatment of lupus (or SLE) is complex, especially for young patients who are committed to take hydroxychloroquine (HCQ) lifelong, which carries some risk, albeit…
Abstract Number: 2684 • ACR Convergence 2024
Assessment of Skin in Patients with Systemic Sclerosis Using High Frequency Ultrasound : A Comparative Study with Histology and Clinical Parameters of Skin Disease
Ruhani Desai¹, Filemon Tan², Minghua Wu³, Jefferey Browning⁴, Samuel Theodore³, Meng Zhang³, Brian Skaug³, Maureen Mayes³ and Shervin Assassi³, ¹UTHealth Houston Division of Rheumatology, DeLand, FL, ²University of Texas at Houston McGovern Medical School, Houston, TX, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴Boston Univeristy, Boston, MA
Background/Purpose: The extent of skin involvement and its rate of progression can provide prognostic information for systemic sclerosis (SSc)-related morbidity and mortality. Moreover, skin assessment…
Abstract Number: 2687 • ACR Convergence 2024
Therapeutic Choices in Systemic Sclerosis Associated Interstitial Lung Disease, a Survey of International Experts
Michael Macklin¹, Iazsmin Bauer Ventura¹ and Dinesh Khanna², ¹University of Chicago, Chicago, IL, ²University of Michigan, Ann Arbor, MI
Background/Purpose: The therapeutic options for systemic sclerosis-associated interstitial lung disease (SSc-ILD) have evolved rapidly, with recent guidelines released by the ACR and American Thoracic Society…
Abstract Number: PP04 • ACR Convergence 2024
Involving Pediatric Patients in Their Own Care
Whitney LaBar, Lupus and Allied Diseases Association, Pleasanton, CA
Background/Purpose: When I was 14, I was diagnosed with thrombocytopenia, which led to more testing and a diagnosis of systemic lupus erythematosus (SLE). As a…
Abstract Number: PP03 • ACR Convergence 2024
How Completing a Systematic Literature Review Improved How I Research My Own Rheumatoid Arthritis and Comorbidities
Shelley Fritz, Global Healthy Living Foundation, Kalaheo, HI
Background/Purpose: Twelve years ago, I was diagnosed with rheumatoid arthritis (RA). Initially, I was hopeful that the first biologic DMARD would slow the disease and…
Abstract Number: PP14 • ACR Convergence 2024
Support Groups and Chronic Illness: Finding Social Support Among Peers
Alexandra Blumhorst¹ and Estela Mata-Carcamo², ¹Looms for Lupus, Silver Spring, MD, ²Looms for Lupus, Irwindale, CA
Background/Purpose: Like many lupus patients, my journey has been long, complex, and difficult. I began experiencing symptoms in 2019. Over the next five years, I…
Abstract Number: PP07 • ACR Convergence 2024
My Journey with Diffuse Scleroderma and Interstitial Lung Disease: A Pharmacist’s Perspective
Joseph Washington, Cencora, Washington, DC
Background/Purpose: Since my diagnosis with diffuse scleroderma and ILD, I have balanced the roles of patient and young pharmacist. A duality that has surely impacted…
Abstract Number: 2686 • ACR Convergence 2024
Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells
David Fox¹, Laura Cooney², Lia Stelzig³, Robert Lafyatis⁴, Johann Gudjonsson⁵, Lam Tsoi⁶, Maureen Mayes⁷, Ankoor Shah⁸, Suzanne Kafaja⁹, William Barry³, Ellen Goldmuntz¹⁰, Dawn Smilek¹¹ and Dinesh Khanna⁶, ¹University of Michigan, Dexter, MI, ²University of Michigan and Immune Tolerance Network, Ann Arbor, MI, ³Rho, Durham, NC, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Dermatology, University of Michigan, Ann Arbor, MI, ⁶University of Michigan, Ann Arbor, MI, ⁷UTHealth Houston Division of Rheumatology, Houston, TX, ⁸Duke University, Durham, NC, ⁹Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ¹⁰Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD, ¹¹Immune Tolerance Network, UCSF, San Francisco, CA
Background/Purpose: Brentuximab vedotin (ADCETRIS®) is a drug antibody conjugate targeting CD30 approved for treatment of Hodgkin’s lymphoma (HL) and other hematologic malignancies. Association of CD30…
Abstract Number: PP02 • ACR Convergence 2024
Living Well with a Rare Rheumatic Disease – Becoming a “Precision” Patient on the Horizon of Precision Medicine
Ida Hakkarinen, self, Greenbelt, MD
Background/Purpose: My journey with a rare, chronic, relapsing rheumatic disease began in November 2010 with a variety of seemingly unrelated symptoms: migrating joint pain, night…
Abstract Number: 2692 • ACR Convergence 2024
Transcriptomic Profiling of Kidney Biopsies Implicates Th17 and IL-17 in ANCA-Associated Vasculitis
Ivana Stojkic¹, Arnon Arazi², Huijuan Song³, Pearlly Yan⁴, Estela Puchulu-Campanella³, Hubao Wang³, Lynn Fussner³, Brad Rovin³, Samir Parikh⁵, Stacy Ardoin⁶, Daniel Koboldt⁷, James Fitch⁷ and Salem Almaani⁸, ¹Nationwide, Columbus, OH, ²Feinstein Institutes for Medical Research, Melrose, MA, ³The Ohio State University, Columbus, OH, ⁴The Ohio State University, Columbus, ⁵Ohio State University, Columbus, OH, ⁶Nationwide Children's Hospital, Columbus, OH, ⁷Steve and Cindy Rasmussen Institute for Genomic Medicine, Columbus, OH, ⁸The Ohio State University Medical Center, Columbus, OH
Background/Purpose: ANCA-associated vasculitis (AAV) is a severe autoimmune disease targeting small vessels, with significant kidney involvement. Despite current therapies, up to 28% of patients progress…
Abstract Number: PP10 • ACR Convergence 2024
Walking Away from Arthritis Pain: Exercise Helped Me Manage Sarcoidosis and Osteoarthritis Physically and Emotionally
Bridget Kelly, Hospital for Special Surgery, Rockville Centre, NY
Background/Purpose: In 2004, we moved to a new home with 2 small children, when I started experiencing terrible joint pain. For 2 years I was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].